Genentech Singapore To Buy Local Lonza Plant To Produce Avastin
This article was originally published in PharmAsia News
Executive Summary
Singapore's Roche subsidiary, Genentech Singapore, plans to buy Lonza Biologics Singapore's cell-culture plant by exercising an option. Roche plans to merge the facility, bought at a cost of $201 million and up to $48.5 million in milestone payments, with Genentech Singapore's separate facility. Roche expects to produce its Avastin (bevacizumab) in bulk for treating several types of cancer. The merger of facilities is to include about 230 Lonza employees to raise the work force at Genentech Singapore to 325. (Click here for more